Navigation Links
FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
Date:7/8/2009

WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for injection) to treat patients with myelodysplastic syndromes (MDS). MDS is a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells.

Currently, Dacogen is approved for use as a three-day regimen, administered at a dose of 15 mg/m2 via continuous IV infusion over three hours repeated every eight hours for three consecutive days per cycle. The cycle is repeated every six weeks. The alternative five-day dosing regimen of Dacogen(R) submitted to the U.S. FDA is a single daily dose with a significantly reduced administration time. If approved, patients with MDS may experience increased convenience with the new dosing regimen.

"We're pleased that the FDA has agreed to review our application for the alternative dosing regimen, and we look forward to working with the agency throughout the review process," said Cynthia Schwalm, President of Eisai Inc. "This application is one part of a full complement of clinical development programs we have committed for Dacogen and is a vital part of our human health care mission of increasing patient benefits and fulfilling unmet medical needs."

Acceptance of the sNDA means that FDA has found the company's submission to be sufficiently complete to review.

About Dacogen

The safety profile of decitabine for injection is well characterized. Dacogen (decitabine for injection) was approved by the FDA on May 2, 2006, and is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2 and High-Risk International Prognostic Scoring System (IPSS) groups.

Dacogen may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using Dacogen. Men should be advised not to father a child while receiving treatment with Dacogen and for two months afterwards. The most commonly occurring adverse reactions with Dacogen include neutropenia (90 percent), thrombocytopenia (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 percent), petechiae (39 percent), constipation (35 percent), and diarrhea (34 percent).

Please visit www.dacogen.com for full prescribing information.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
2. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
3. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
4. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
5. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
6. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
7. New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients
8. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
9. Gallbladder Removal Through Vagina Offers Minimally Invasive Alternative
10. Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives
11. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- A Small Business Innovative Research (SBIR) grant has ... to Phoenix -based NeuroEM Therapeutics, Inc. ... will seek to determine an optimal set of treatment ... to treat Alzheimer,s Disease. The grant will also investigate ... other neurologic disorders such as Parkinson,s Disease and PTSD. ...
(Date:12/8/2016)... in the United States will continue in 2017, say ... December 2016 Semiannual Economic Forecast. Expectations are for a ... as indicated in the monthly ISM ® ... is optimistic about growth in 2017, with revenues expected ... sector indicates that 14 of its industries will see ...
(Date:12/8/2016)...  Hanson Research, an innovative leader in the ... testing instruments for the pharmaceutical industry, announced today ... ("Teledyne"). The move is designed to deepen investments ... as well as expand resources for further market ... services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... set up in 2006 as a non-profit organization to unite pharmaceutical and healthcare ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. ... advocates for the mass media launching of story movements to highlight what's most ... their unfortunate experiences; such a movement can generate the network power to improve ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated ... it is one of the early adopters completing EU-U.S. Privacy Shield Certification from the ... provide companies on both sides of the Atlantic with a mechanism to comply with ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is ... by smoothing and tightening the skin of the face to create more youthful ... aging with very little downtime, Silhouette Instalift is a novel, minimally invasive facial ...
Breaking Medicine News(10 mins):